Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer

• ClinicalTrials.gov Identifier: NCT01025453
• Recruitment Status: Completed
• First Posted: December 3, 2009
• Results First Posted: August 15, 2018
• Last Update Posted: August 15, 2018
• Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborators: National Comprehensive Cancer Network; Pfizer
• Information provided by (Responsible Party): Memorial Sloan Kettering Cancer Center

Study Description

Brief Summary:

The purpose of this study is to find out what effects, good and/or bad, the combination of sorafenib and temsirolimus will have on thyroid cancer. Treatment guidelines from the National Comprehensive Cancer Network include sorafenib as a treatment option for thyroid cancer.

Temsirolimus is an intravenous medication that is FDA approved for other type of cancers. In laboratory studies, the addition of temsirolimus to sorafenib works better than sorafenib alone.

Condition or disease	Intervention/treatment	Phase
Thyroid Cancer	Drug: Temsirolimus and Sorafenib	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 37 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
• Actual Study Start Date: December 1, 2009
• Actual Primary Completion Date: January 16, 2018
• Actual Study Completion Date: January 16, 2018

Arms and Interventions

Arm

Intervention/treatment

Experimental: Pts getting Temsirolimus and Sorafenib; We propose a phase II study to evaluate the efficacy of the combination sorafenib with temsirolimus in patients with thyroid cancer of follicular cell origin (e.g., papillary, follicular, Hurthle cell). A maximum of 36 subjects will be evaluated during the study. Restaging scans, with evaluation of response, will be done every 2 cycles (8 weeks of treatment). Treatment will continue until clinical disease progression, unacceptable toxicity, treatment delay > 4 weeks, or at the discretion of the treating physician or patient.

Drug: Temsirolimus and Sorafenib; Treatment will be with sorafenib 200 mg orally twice a day and temsirolimus 25 mg intravenous weekly. A cycle will be equivalent to 4 weeks of treatment.

Outcome Measures

Primary Outcome Measures :

1. Reponse Rate of the Combination Sorafenib and Temsirolimus in I-131 Refractory Thyroid Cancer. [ Time Frame: 2 years ]
   Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Secondary Outcome Measures :

1. Duration of Study Treatment for Participants With and Without BRAF Mutations [ Time Frame: 6 years ]
2. Percentage of Participants With Progression-free Survival Under the Combination Sorafenib and Temsirolimus in I-131 Refractory Thyroid Cancer. [ Time Frame: 1 year ]
   Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
3. Safety and Tolerability for the Combination Sorafenib and Temsirolimus in I-131 Refractory Thyroid Cancer. [ Time Frame: 3 years ]
   Participant toxicities evaluated by CTCAE version 4.0

Eligibility Criteria

• Ages Eligible for Study: 21 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Patients must have histopathologically confirmed at MSKCC thyroid carcinoma of follicular cell origin (D-TC-FCO), which includes papillary, follicular, Hürthle cell histology, or anaplastic along with their respective variants.
• Available pathology for RAF mutational testing (e.g., paraffin block or 5-10 unstained slides). It is not required that mutational testing be completed before starting the clinical study.
• Patients must have surgically inoperable and/or recurrent/metastatic disease.
• Patients must have a PET scan prior to the protocol start date and have at least one FDGavid lesion that has not been removed surgically or radiated (unless it has progressed by RECIST criteria after the completion of radiation therapy and is still FDG-avid). FDGavidity will be defined as any focus of increased FDG uptake greater than normal activity with SUV maximum levels greater than or equal to 3. PET scan can have been done at any time prior to the start of therapy, although it is recommended that it be done within 3 months prior to the start of therapy.
• Patients must have measurable disease by RECIST criteria, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan; performed ≤ 4 weeks of protocol start date.
• Patients must have progressive disease defined by at least one of the following occurring during or after previous treatment (including RAI treatment):
• The presence of new or progressive lesions on CT/MRI.
• New lesions on bone scan or PET scan.
• Rising thyroglobulin level (documented by a minimum of three consecutive rises, with an interval of > 1 week between each determination).
• Prior RAI therapy is allowed if > 3 months prior to initiation of therapy on this protocol and evidence of progression (as defined above) has been documented in the interim. A diagnostic study using <10 mCi of RAI is not considered RAI therapy.
• Patients may have received prior external beam radiation therapy to index lesions ≥ 4 weeks prior to initiation of therapy on this protocol if there has been documented progression by RECIST criteria. Prior external beam radiation therapy to the non-index lesions is allowed if ≥ 4 weeks prior to initiation of therapy on this protocol.
• ECOG performance status ≤ 2 (or Karnofsky performance status ≥ 60%).
• Patients must have normal organ and marrow function as defined below:
• Absolute neutrophil count ≥1,500/mcL
• Platelets ≥100,000/mcL
• Total bilirubin ≤ 1.5 X institutional ULN
• AST(SGOT)/ALT(SGPT) ≤ 2.5 X institutional ULN
• Creatinine ≤ 1.5 X institutional ULN OR
• Creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above 1.5 X institutional ULN [in this circumstance, either of a measured level based on a 24 hour urine collection, or a calculated level using the Cockcroft and Gault equation: (140 - age in years) X (weight in kg) X (0.85 if female)/72 X serum Cr may be used].
• International normalized ratio (INR) ≤ 1.5 (or in range INR, usually between 2 and 3, if patient is on a stable dose of therapeutic warfarin).
• *ULN = upper limit of normal
• **unless liver metastasis present in which AST/ALT should be < 5 x ULN.
• Ability to understand and the willingness to sign a written informed consent document.
• Age 21 years old or older.

Exclusion Criteria:

• Patients may not be receiving any other investigational agents.
• Patients with known history of active intraparenchymal brain metastasis within previous 3 months.
• Serious or non-healing wound, ulcer, or bone fracture.
• History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days of treatment.
• Patients with a reported history of clinically active diverticulosis or diverticulitis in the prior 3 years.
• Patients with clinically significant cardiovascular disease as defined by the following:
• History of CVA within past 6 months
• Myocardial infarction, CABG or unstable angina within past 6 months
• New York Heart Association grade III or greater congestive heart failure or Canadian Cardiovascular Class grade III or greater angina within past 6 months (Appendices B&C) Clinically significant peripheral vascular disease within past 6 months
• Pulmonary embolism, DVT, or other thromboembolic event within past 6 months
• Uncontrolled coronary artery disease, angina, congestive heart failure, or ventricular arrhythmia requiring acute medical management within past 6 months
• History of myocardial infarct, cerebrovascular accident, or transient ischemic event within the past 6 month
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements.
• While the use of Angiotensin-Converting Enzyme (ACE) inhibitors is not absolutely excluded, efforts should be made to see if patients on ACE inhibitors can be taken off the medication or switched to another medication.
• Pregnant women will be ineligible; breastfeeding should be discontinued if the mother is treated with study drugs.
• The use of agents that inhibit or induce CYP3A metabolism is not strictly prohibited, but should be avoided if possible. Potential CYP3A inducing agents include carbamazepine, phenytoin, barbiturates, rifabutin, rifampicin, and St. John's Wort. Potential CYP3A inhibitors include protease inhibitors, antifungals, macrolide antibiotics, nefazodone, and selective serotonin inhibitors.

Contacts and Locations

Locations

United States, New Jersey

Memorial Sloan-Kettering at Basking Ridge

Basking Ridge, New Jersey, United States, 07920

United States, New York

Memorial Sloan-Kettering Cancer Center @ Suffolk

Commack, New York, United States, 11725

Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10065

Memorial Sloan-Kettering at Mercy Medical Center

Rockville Centre, New York, United States

Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center

Sleepy Hollow, New York, United States, 10591

Sponsors and Collaborators

Memorial Sloan Kettering Cancer Center

National Comprehensive Cancer Network

Pfizer

Investigators

• Principal Investigator: Eric Sherman, MD; Memorial Sloan Kettering Cancer Center

  Study Documents (Full-Text)

Documents provided by Memorial Sloan Kettering Cancer Center:

Study Protocol and Statistical Analysis Plan  [PDF] May 12, 2015

More Information

Additional Information:

Memorial Sloan Kettering Cancer Center 

• Responsible Party: Memorial Sloan Kettering Cancer Center
• ClinicalTrials.gov Identifier: NCT01025453
• Other Study ID Numbers: 09-148
• First Posted: December 3, 2009
• Results First Posted: August 15, 2018
• Last Update Posted: August 15, 2018
• Last Verified: July 2018

Keywords provided by Memorial Sloan Kettering Cancer Center:

thyroid; follicular cell; papillary cell; Hurthle cell; BAY 43-9006; Temsirolimus; Sorafenib; 09-148

Additional relevant MeSH terms:

Thyroid Neoplasms; Thyroid Diseases; Endocrine System Diseases; Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Head and Neck Neoplasms; Sirolimus; Sorafenib; Temsirolimus; MTOR Inhibitors; Antineoplastic Agents; Protein Kinase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antineoplastic; Antifungal Agents